Cytodyn Inc (CYDY)

[gestalt2]

Why exit? does the science of pro 140 not work with a RS? is HIV become an non-existent problem with a RS?

I understand that many believe and have a long list of examples of when a RS caused nothing but a dropping SP. However, a RS typically is used for a company to stay in a market they may fall off of because of fundamental problems. That is not the case with CYDY as far as we know. Being on the otc has been a major problem for the past couple years and mgmt is solving it with a RS because an organic SP rise has been impossible on the otc. Can you think of a good reason that being on the otc is better? Which would you rather have, the ability to short and allow larger institutional buyers to invest or no institutional buyers and less shorting? More liquidity and exposure to a real market is always better.